Uri Weinberg sold $85k of NVCR
Chf Medical and Innovation Ofr at NovoCure Ltd. 6,412 shares at an average of $13.31, traded Mar 4, 2026, filed Mar 5, 2026.
Score components
- +15RoleOfficer
- +9Trade size$85k at market
- 0Share of holdings soldSold 2.3% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -25.9%, 3m +26.4%, 6m +24.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001811030-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | AGrant or award Ordinary Shares | +50,125 | $0.00 | $0 | 273,602 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Ordinary Shares | -6,412 | $13.31 | $85k | 267,190 | Mar 5, 2026 |
| Mar 3, 2026 | AGrant or award Stock Option (Right to Buy)derivative | +73,340 | $0.00 | $0 | 73,340 | Mar 5, 2026 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | NovoCure Ltd | Frank X Leonard Chief Executive Officer | $615k 34,273 shares | -7% | |
| 41Moderate | NovoCure Ltd | Jeryl L Hilleman director | $46k 2,945 shares | -18% | |
| 41Moderate | NovoCure Ltd | David Hung director | $46k 2,945 shares | -13% | |
| 36Weak | NovoCure Ltd | Gabriel Leung director | $46k 2,945 shares | -3% | |
| 36Weak | NovoCure Ltd | W Anthony Vernon director | $46k 2,945 shares | -1% | |
| 41Moderate | NovoCure Ltd | Timothy J Scannell director | $46k 2,945 shares | -17% | |
| 41Moderate | NovoCure Ltd | Allyson J Ocean director | $46k 2,945 shares | -21% | |
| 41Moderate | NovoCure Ltd | Kristin Stafford director | $46k 2,945 shares | -21% | |
| 46Moderate | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 64Notable | NovoCure Ltd | William F Doyle Executive Chairman | $933k 71,887 shares | -18% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.